Skip to main content

Table 3 Laboratory and radiologic findings of included patients

From: Clinical characteristics of inpatients with coronavirus disease 2019 (COVID-19) in Sichuan province

  Diagnosis Disease severity
  Suspected
(n = 22)
Laboratory-confirmed
(n = 147)
Non-severe
(n = 122)
Severe
(n = 25)
P value#
Laboratory findings at first test
White blood cell count, median (IQR), × 109/L 6·7 (5·0–9·6) 5·0 (4·0–6·1) 4·9 (4·0–6·0) 5·3 (4·5–7·4) 0·054
  > 10×  109/L, No·/total (%) 3/13 (23·1) 9/145 (6·2) 4/120 (3·3) 5/25 (20·0) 0·0070
  < 4× 109/L, No·/total (%) 2/13 (15·4) 18/145 (12·4) 15/120 (12·5) 3/25 (12·0) >  0·99
Lymphocyte count, median (IQR), × 109/L 1·00 (0·80–1·20) 1·14 (0·90–1·60) 1·20 (1·00–1·70) 0·80 (0·50–1·00) <  0·0001
  < 1·1×  109/L, No·/total (%) 6/11 (54·5) 71/143 (49·7) 52/119 (43·7) 19/24 (79·2) 0·0030
Eosinophils count, median (IQR), × 109/L 0·02 (0·00–0·05) 0·01 (0·00–0·05) 0·02 (0–0·05) 0·00 (0·00–0·01) 0·0030
  <  0·02×  109/L, No·/total (%) 6/11 (54·5) 81/133 (60·9) 65/114 (57·0) 16/19 (84·2) 0·046
Haemoglobin, median (IQR), g/L 133 (125–151) 142 (127–156) 144 (128–155) 142 (124–157) 0·87
  < 130 g/L, No·/total (%) 6/13 (46·2) 42/143 (29·4) 34/118 (28·8) 8/25 (32·0) 0·94
International normalised ratio, median (IQR) 1·05 (0·97–1·08) 1·04 (0·97–1·13) 1·03 (0·97–1·13) 1·04 (1·00–1·11) 0·58
  > 1·26, No·/total (%) 0/7 (0·0) 6/125 (4·8) 6/108 (5·6) 0/17 (0·0) >  0·99*
D-dimer, median (IQR), μg/L 390 (280–430) 195 (93–403) 175 (90–368) 414 (163–930) 0·025
  > 550 μg/L, No·/total (%) 1/5 (20·0) 22/122 (18·0) 16/104 (15·4) 6/18 (33·3) 0·13
Albumin, median (IQR), g/L 41·2 (34·7–45·1) 43·7 (40·9–46·1) 44·2 (42·1–46·9) 38·2 (35·3–43·8) <  0·0001
  < 35 g/L, No·/total (%) 3/12 (25·0) 7/136 (5·2) 2/114 (1·6) 5/22 (22·7) <  0·0001
Alanine aminotransferase, median (IQR), U/L 22 (15–25) 26 (17–46) 26 (17–46) 29 (21–41) 0·46
  > 50 U/L, No·/total (%) 0/10 (0·0) 26/136 (19·1) 21/116 (18·1) 5/20 (25·0) 0·68
Aspartate aminotransferase, median (IQR), U/L 24 (22–30) 26 (20–35) 26 (20–36) 25 (21–34) 0·64
  > 40 U/L, No·/total (%) 0/8 (0·0) 18/108 (16·7) 15/91 (16·5) 3/17 (17·6) >  0·99*
Total bilirubin, median (IQR), μmol/L 9·7 (6·0–18·0) 10·5 (7·0–16·9) 10·8 (7·0–16·5) 8·7 (7·0–18·3) 0·94
  > 28 μmol/L, No·/total (%) 1/12 (8·3) 9/135 (6·7) 7/116 (6·3) 2/19 (10·5) 0·81
Direct bilirubin, median (IQR), μmol/L 3·9 (2·8–7·3) 4·0 (2·7–5·8) 3·9 (2·6–5·4) 4·0 (3·0–6·7) 0·30
  > 10 μmol/L, No·/total (%) 2/12 (16·7) 9/135 (6·7) 7/116 (6·0) 2/19 (10·5) 0·82
Serum creatinine, median (IQR), μmol/L 80·5 (69·3–89·3) 74·3 (59·7–83·5) 72·5 (59·0–83·5) 76·2 (63·8–83·5) 0·57
  > 106 μmol/L, No·/total (%) 1/12 (8·3) 5/132 (3·8) 4/112 (3·8) 1/20 (5·0) 0·57*
Troponin T, median (IQR), pg/mL 3·00 (1·10–47·12) 3·00 (0·03–9·7) 3·00 (0·03–9·15) 6·13 (0·23–13·40) 0·23
  > 14 pg/mL, No·/total (%) 3/7 (42·9) 8/80 (10·0) 5/67 (7·5) 3/13 (23·1) 0·23
Procalcitonin, median (IQR), ng/mL 0·04 (0·03–0·21) 0·05 (0·03–0·06) 0·05 (0·03–0·06) 0·05 (0·02–0·08) 0·56
  >  0·05 ng/mL, No·/total (%) 4/13 (30·8) 45/128 (35·2) 36/107 (33·6) 9/21 (42·9) 0·58
Erythrocyte sedimentation rate, median (IQR), mm/h 27 (21–51) 22 (10–36) 21 (10–33) 23 (7–44) 0·77
  > 15 mm/h, No·/total (%) 9/11 (81·8) 64/102 (62·7) 54/88 (61·4) 10/14 (71·4) 0·67
C-reactive protein, median (IQR), mg/L 7·6 (0·9–31·8) 7·2 (2·0–24·2) 5·7 (1·9–15·6) 31·7 (14·2–54·2) < 0·0001
Procalcitonin, median (IQR), ng/mL 0·04 (0·03–0·21) 0·05 (0·03–0·06) 0·05 (0·03–0·06) 0·05 (0·02–0·08) 0·56
  >  0·05 ng/mL, No·/total (%) 4/13 (30·8) 45/128 (35·2) 36/107 (33·6) 9/21 (42·9) 0·58
Erythrocyte sedimentation rate, median (IQR), mm/h 27 (21–51) 22 (10–36) 21 (10–33) 23 (7–44) 0·77
  > 15 mm/h, No·/total (%) 9/11 (81·8) 64/102 (62·7) 54/88 (61·4) 10/14 (71·4) 0·67
C-reactive protein, median (IQR), mg/L 7·6 (0·9–31·8) 7·2 (2·0–24·2) 5·7 (1·9–15·6) 31·7 (14·2–54·2) < 0·0001
  > 5 mg/L, No·/total (%) 6/12 (50·0) 62/122 (50·8) 44/102 (43·1) 18/20 (90·0) < 0·0001
CKMBa
  Increased, No·/total (%) 2/11 (18·2) 7/91 (7·7) 6/79 (7·6) 1/12 (8·3) >  0·99*
Gamma-glutamyltran sferase, median (IQR), U/L 20 (18–34) 30 (17–57) 29 (16–46) 33 (17–73) 0·350
Lactate dehydrogenase, median (IQR), U/L 245 (179–276) 187 (167–233) 184 (163–227) 229 (190–400) 0·015
Potassium, median (IQR), mmol/L 4·2 (3·8–4·3) 3·8 (3·6–4·1) 3·8 (3·6–4·1) 3·8 (3·4–4·1) 0·86
Sodium, median (IQR), mmol/L 140 (136–142) 139 (136–141) 139 (137–141) 137 (135–139) 0·011
Radiologic findings
Abnormalities at first examination, No./total (%) 13/14 (92·9) 113/129 (87·6) 94/109 (86·2) 19/20 (95·0) 0·47
  Bilateral pneumonia 10/14 (71·4) 87/129 (67·4) 68/109 (62·4) 19/20 (95·0) 0·0090
  Unilateral pneumonia 3/14 (21·4) 26/129 (20·2) 26/109 (23·9) 0/20 (0·0) 0·032
  Ground-glass opacity 6/14 (42·9) 89/129 (69·0) 73/109 (67·0) 16/20 (80·0) 0·37
  Patchy or stripes shadowing 10/14 (71·4) 89/129 (69·0) 75/109 (68·8) 14/20 (70·0) >  0·99*
  Parenchymal abnormalities 2/14 (14·3) 21/129 (16·3) 16/109 (14·7) 5/20 (25·0) 0·41
  Pleural effusion 0/14 (0·0) 5/129 (3·9) 2/109 (1·8) 3/20 (15·0) 0·026*
Abnormalities during hospitalization, No./total (%) 13/14 (92·9) 118/132 (89·4) 98/112 (87·5) 20/20 (100·0) 0·20
  Bilateral pneumonia 11/14 (78·6) 101/132 (76·5) 81/112 (72·3) 20/20 (100·0) 0·016
  Unilateral pneumonia 2/14 (14·3) 17/132 (12·9) 17/112 (15·2) 0/20 (0·0) 0·13
  Ground-glass opacity 7/14 (50·0) 98/132 (74·2) 80/112 (71·4) 18/20 (90·0) 0·14
  Patchy or stripes shadowing 12/14 (85·7) 103/132 (78·0) 87/112 (77·7) 16/20 (80·0) >  0·99*
  Parenchymal abnormalities 2/14 (14·3) 31/132 (23·5) 25/112 (22·3) 6/20 (30·0) 0·65
  Pleural effusion 0/14 (0·0) 6/132 (4·5) 3/112 (2·7) 3/20 (15·0) 0·045*
  1. Abbreviations: IQR Interquartile range, CKMB Creatine Kinase-MB
  2. * The P-value was derived from Fisher’s exact test, two-sided; # P-value for the comparison between severe cases versus non- severe infected patients; aClassified by different reference range of hospitals
\